Incyte Corp (MIL:1INCY)
€ 66.84 0 (0%) Market Cap: 13.69 Bil Enterprise Value: 12.09 Bil PE Ratio: 541.07 PB Ratio: 4.61 GF Score: 70/100

Incyte Corp at Guggenheim Biopharma's Next Decade Virtual Conference Transcript

Jun 28, 2021 / 03:00PM GMT
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

Okay. Hello, and welcome to this meeting with Incyte management as part of our 2021 Biopharma

Strategy Series. I'm Mike Schmidt, senior biotech analyst with Guggenheim. And with us today, we have Incyte's CEO, Herve Hoppenot as well as Christiana Stamoulis, the CFO. Welcome, guys, and thanks for joining us today.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

No, thank you for inviting us.

Questions & Answers

Michael Werner Schmidt;
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

So Herve, maybe just starting out with a few general questions, and then I have a whole bunch of questions about the different products and pipeline assets. But starting out, as Jakafi continues to build a very strong commercial foundation for Incyte, could you just walk us through your long-term growth strategy and how it has evolved in recent years?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot